Skip to content

On this page

Veopoz

pozelimab-bbfg

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Veopoz

Proper name

pozelimab-bbfg

Licence type

351(a)

BLA number

761339

Applicant

Regeneron Pharmaceuticals, Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
400MG/2ML (200MG/ML)	Injection	Intravenous, Subcutaneous	Single-Dose Vial	Rx	August 18, 2023

Exclusivity

Source: Purple Book

Kind	Expires
Orphan exclusivity	August 18, 2030

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity